BR0009805A - Mutações de enos úteis para terapia genética e rastreamento terapêutico - Google Patents

Mutações de enos úteis para terapia genética e rastreamento terapêutico

Info

Publication number
BR0009805A
BR0009805A BR0009805-1A BR0009805A BR0009805A BR 0009805 A BR0009805 A BR 0009805A BR 0009805 A BR0009805 A BR 0009805A BR 0009805 A BR0009805 A BR 0009805A
Authority
BR
Brazil
Prior art keywords
proteins
nos
peptides
gene therapy
useful
Prior art date
Application number
BR0009805-1A
Other languages
English (en)
Inventor
William C Sessa
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of BR0009805A publication Critical patent/BR0009805A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C12N9/0075—Nitric-oxide synthase (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MUTAçõES DE eNOS UTéIS PARA TERAPIA GENéTICA E RASTREAMENTO TERAPêUTICO". A presente invenção se relaciona com novas variantes ou mutantes de NOS que contêm alterações estruturais no sítio de fosforilação dependente de Akt. As proteínas ou peptídeos de NOS alterados, especialmente as proteínas ou peptídeos de eNOS humana, proteínas ou polipeptídeos de Akt e suas moléculas de ácido nucleico codificadoras são úteis como agentes de terapia genética para o tratamento de doenças que incluem re-estenose pós-angioplastia, hipertensão, arteriosclerose, falência cardíaca, diabetes e doenças com angiogênese defeituosa. As proteínas e peptídeos de NOS também são úteis em métodos de rastreamento para agentes que modulam a atividade de NOS.
BR0009805-1A 1999-04-16 2000-04-14 Mutações de enos úteis para terapia genética e rastreamento terapêutico BR0009805A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12955099P 1999-04-16 1999-04-16
PCT/US2000/009913 WO2000062605A1 (en) 1999-04-16 2000-04-14 eNOS MUTATIONS USEFUL FOR GENE THERAPY AND THERAPEUTIC SCREENING

Publications (1)

Publication Number Publication Date
BR0009805A true BR0009805A (pt) 2002-01-15

Family

ID=22440541

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009805-1A BR0009805A (pt) 1999-04-16 2000-04-14 Mutações de enos úteis para terapia genética e rastreamento terapêutico

Country Status (25)

Country Link
US (4) US6900038B2 (pt)
EP (1) EP1178722A4 (pt)
JP (1) JP2002541829A (pt)
KR (1) KR100737945B1 (pt)
CN (1) CN100357433C (pt)
AU (2) AU774010B2 (pt)
BG (1) BG106051A (pt)
BR (1) BR0009805A (pt)
CA (1) CA2369764A1 (pt)
CZ (1) CZ20013427A3 (pt)
EE (1) EE200100538A (pt)
HK (1) HK1046081B (pt)
HR (1) HRP20010797A2 (pt)
HU (1) HUP0200799A3 (pt)
IL (1) IL145760A0 (pt)
MX (1) MXPA01010459A (pt)
NO (1) NO20015008L (pt)
NZ (1) NZ514305A (pt)
PL (1) PL351087A1 (pt)
RU (1) RU2257226C2 (pt)
SK (1) SK14692001A3 (pt)
UA (1) UA76939C2 (pt)
WO (1) WO2000062605A1 (pt)
YU (1) YU73301A (pt)
ZA (1) ZA200108463B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100357433C (zh) * 1999-04-16 2007-12-26 耶鲁大学 可用于基因治疗和治疗性筛选的eNOS突变
AU2003276711A1 (en) 2002-06-14 2003-12-31 Wisconsin Alumni Research Foundation Ribonuclease zymogen design
PL375219A1 (en) * 2002-08-16 2005-11-28 Schering Aktiengesellschaft Enos mutants useful for gene therapy
CA2494845A1 (en) * 2002-08-16 2004-02-26 Schering Aktiengesellschaft Gene therapy for critical limb ischemia with wild type or mutant enos
GB0226463D0 (en) * 2002-11-13 2002-12-18 Isis Innovation Mimicking the athletic heart
ATE474604T1 (de) * 2002-12-02 2010-08-15 Anges Mg Inc Zusammensetzungen zur behandlung oder prävention von angiogenese-abhängigen symptomen
WO2006023879A1 (en) * 2004-08-20 2006-03-02 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults
MX2007003522A (es) 2004-09-24 2007-06-11 Beth Israel Hospital Complicaciones del embarazo.
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
BRPI0713122A2 (pt) * 2006-05-31 2012-04-17 Beth Israel Hospital métodos de diagnóstico e tratamento de complicações de gravidez
WO2010011607A1 (en) 2008-07-22 2010-01-28 Promega Corporation Adp detection based luminescent phosphotransferase or atp hydrolase assay
EP2374005A1 (en) * 2008-12-04 2011-10-12 Sanofi Methods and uses involving heme binding protein 1
RU2526575C2 (ru) * 2012-11-02 2014-08-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ повышения иммуносупрессивных свойств мезенхимальных стромальных клеток жировой ткани
JP6510041B2 (ja) 2014-10-08 2019-05-08 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ 生物発光サクシネート検出アッセイ
CN107802826B (zh) * 2017-10-26 2020-02-18 首都医科大学宣武医院 eNOS突变体在促进血管生成中的应用
CN116790603B (zh) * 2023-08-18 2023-10-31 成都中科奥格生物科技有限公司 一种sgRNA、CRISPR/Cas9载体及其构建方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498539A (en) * 1992-07-02 1996-03-12 Daiichi Pharmaceutical Co., Ltd. Bovine endothelial nitric oxide synthase nucleic acids
US5658565A (en) * 1994-06-24 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase gene for treatment of disease
DE4411402A1 (de) * 1994-03-31 1995-10-05 Juergen Schrader DNA-Expressionsvektoren zur Verwendung in der gentherapeutischen Behandlung von Gefäßerkrankungen
FR2722507B1 (fr) * 1994-07-12 1996-08-14 Rhone Poulenc Rorer Sa Adenovirus comportant un gene codant pour une no synthase
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US5837534A (en) * 1995-11-14 1998-11-17 The Board Of Regents Of The University Of Texas System Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells
DE69928820D1 (de) * 1998-10-02 2006-01-12 Caritas St Elizabeths Boston Akt zusammensetzungen zur steigerung des überlebens von kardiomyozyten
CA2343074C (en) * 1999-03-19 2010-09-21 Aventis Pharmaceuticals Products Inc. Akt nucleic acids, polypeptides, and uses thereof
CN100357433C (zh) * 1999-04-16 2007-12-26 耶鲁大学 可用于基因治疗和治疗性筛选的eNOS突变
WO2000077190A2 (en) * 1999-06-11 2000-12-21 Aventis Pharmaceuticals Products Inc. Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt

Also Published As

Publication number Publication date
CA2369764A1 (en) 2000-10-26
KR100737945B1 (ko) 2007-07-13
HK1046081A1 (en) 2002-12-27
MXPA01010459A (es) 2003-08-20
US20110173711A1 (en) 2011-07-14
SK14692001A3 (sk) 2002-09-10
WO2000062605A1 (en) 2000-10-26
HUP0200799A3 (en) 2004-11-29
AU2004210533A1 (en) 2004-11-04
EE200100538A (et) 2002-12-16
AU4237800A (en) 2000-11-02
EP1178722A4 (en) 2003-03-05
YU73301A (sh) 2004-07-15
NO20015008D0 (no) 2001-10-15
US7888089B2 (en) 2011-02-15
PL351087A1 (en) 2003-03-24
HUP0200799A2 (en) 2002-06-29
IL145760A0 (en) 2002-07-25
AU774010B2 (en) 2004-06-10
RU2257226C2 (ru) 2005-07-27
US20030049823A1 (en) 2003-03-13
ZA200108463B (en) 2003-01-15
UA76939C2 (en) 2006-10-16
BG106051A (en) 2002-06-28
KR20010110770A (ko) 2001-12-13
US20090246183A1 (en) 2009-10-01
JP2002541829A (ja) 2002-12-10
CN100357433C (zh) 2007-12-26
EP1178722A1 (en) 2002-02-13
NZ514305A (en) 2004-01-30
CZ20013427A3 (cs) 2002-03-13
US6900038B2 (en) 2005-05-31
HRP20010797A2 (en) 2003-02-28
US20040253685A1 (en) 2004-12-16
CN1347283A (zh) 2002-05-01
NO20015008L (no) 2001-12-07
HK1046081B (zh) 2008-09-05

Similar Documents

Publication Publication Date Title
BR0009805A (pt) Mutações de enos úteis para terapia genética e rastreamento terapêutico
Kao et al. A peptide derived from the amino terminus of endothelial-monocyte-activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response
JP2702811B2 (ja) 改変型毛様体神経栄養因子
DE69836131D1 (de) Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen
PT891331E (pt) Derivados do acido n-(2-oxoacetil ou sulfonil)-pirrolidino/piperidina-2-carboxilico com actividade melhorada de resistencia a multifarmacos
BR0315666A (pt) Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos
DE69422726D1 (de) Peptidverbindungen und ihre therapeutische verwendung als inhibitoren von metalloproteinasen
WO2004053079A3 (en) Compositions, splice variants and methods relating to ovarian specific genes and proteins
DE69434988D1 (de) Tumornekrose-faktor-gamma
MX2010008050A (es) Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos.
DE69838905D1 (de) Transkriptionsfaktor islet-brain 1 (ib1)
Nadendla Principles of organic medicinal chemistry
Kullander et al. Two restricted sites on the surface of the nerve growth factor molecule independently determine specific TrkA receptor binding and activation
AU2004205659B2 (en) MNTF peptides and compositions and methods of use
WO2004005475A3 (en) Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same
DE69534705D1 (de) Dickdarm spezifische gene und proteine
WO2004053075A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
WO2004050860A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
EA200700346A1 (ru) Бактериофаг- и профаг-специфические протеины в генной терапии рака
CY1110911T1 (el) Ανθρωπινο γονιδιο tsc403
WO2004013311A3 (en) Compositions and methods relating to ovarian specific genes and proteins
WO2003083076A3 (en) Polynucleotides encoding novel two splice variants of a human cell surface protein with immunologobulin folds, bgs5g and bgs5i
Tsuchiya et al. Identification of the active portion of the CCL3 derivative reported to induce antitumor abscopal effect
WO2004050858A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
BR9912018A (pt) Uso de uma molécula de ácido nucleico, molécula de ácido nucleico, composição farmacêutica, método de tratamento de distúrbios de proliferação celular associados com a cura de feridas em um mamìfero, incluido o ser humano, e, uso de um polipeptìdeo nab1 ou nab2

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A E 11A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2138 DE 27/12/2011 E CONSIDERANDO A AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS. INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE.